# Germany Retina Health Market

> Germany Retina Health Market Research Report By Treatment (Drugs, Therapy, Surgery) and By Disease Indication (Age-Related Macular Degeneration, Diabetic Retinopathy, Inherited Retinal Diseases, Retinoblastoma) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.97%
- **2024:** $ 1,120 Million
- **2025:** $ 1,198.06 Million
- **2035:** $ 2,350 Million
- **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Santen Pharmaceutical (JP), Carl Zeiss AG (DE), Hoya Corporation (JP)

**Report ID:** MRFR/HC/48362-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/germany-retina-health-market-50119

---

## Market Summary

## **Germany Retina Health Market Overview**

As per MRFR analysis, the Germany Retina Health Market Size was estimated at 0.87 (USD Billion) in 2023. The Germany Retina Health Market Industry is expected to grow from 1.17(USD Billion) in 2024 to 2.07 (USD Billion) by 2035. The Germany Retina Health Market CAGR (growth rate) is expected to be around 5.369% during the forecast period (2025 - 2035).

### **Key Germany Retina Health Market Trends Highlighted**

Significant changes are occurring in the Germany [Retina Health Market](../../../reports/retina-health-market-10913) as a result of numerous important market factors. Macular degeneration and diabetic retinopathy are two age-related retinal illnesses that are becoming more common as the population ages and the proportion of those over 65 rises. By implementing programs to increase access to retinal health treatments, the German government has highlighted the significance of managing eye health and matched public health goals with technological breakthroughs in medicine.

Strong research and development expenditures are also driving advancements in therapeutic and diagnostic approaches, giving medical professionals more effective tools to treat retinal diseases. Routine eye exams and early treatment of eye illnesses are in high demand due to recent developments showing the general public's increased knowledge of eye health and preventive care. In Germany, telemedicine and digital health solutions are becoming more popular, providing patients with quicker access to retinal specialists and consultations without requiring lengthy travel.

The trend towards patient-centric care is reflected in the growing emphasis on creating user-friendly equipment that enables at-home monitoring of retinal diseases by manufacturers and healthcare professionals. In order to improve the standard of treatment for patients with retinal disorders, collaborations between technology developers and healthcare providers might be used to investigate opportunities in the German retinal health market.

Along with increasing training programs for medical professionals in retinal health, there is also the possibility of bettering therapy paths for illnesses for which there are now no effective medicines. Taking advantage of these chances can improve patient outcomes and promote a national strategy for managing retinal health as Germany continues to place a high priority on healthcare innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Germany Retina Health Market Drivers**

#### **Increase in Aging Population Impacting Germany Retina Health Market Industry**

Germany is witnessing a significant demographic shift, with the proportion of elderly individuals steadily increasing. According to the Federal Statistical Office, the population aged 65 and older is projected to rise from 21% in 2020 to approximately 27% by 2035. This rising age demographic correlates with a higher prevalence of age-related conditions such as macular degeneration and diabetic retinopathy, which demand advanced treatments and healthcare solutions within the Germany Retina Health Market Industry.

Established organizations like Novartis and Bayer, which invest heavily in Research and Development (R&D) for retinal therapies, play a pivotal role in addressing these healthcare needs. With an increasing number of patients requiring specialized eye care, the surge in the aging population is a driving force behind the growth of this market, leading to higher investments in innovative treatments and healthcare services.

#### **Advancements in Medical Technology Driving Innovation in Germany Retina Health Market Industry**

The rapid advancement in medical technologies, particularly in diagnostic imaging and treatment options for retinal diseases, is significantly impacting the growth of the Germany Retina Health Market Industry. Innovations such as Optical Coherence Tomography (OCT) have improved the ability to diagnose retinal diseases early, enabling timely intervention. The Federal Ministry of Health has emphasized the role of technology in improving patient outcomes.

With key players like Siemens Healthineers and Heidelberg Engineering at the forefront, the integration of artificial intelligence in diagnostics further enhances the capabilities of eye care professionals. As the demand for cutting-edge technologies continues to rise, investments in these advancements are expected to strengthen the market, making treatment more accessible and efficient.

#### **Increased Awareness and Screening Initiatives in Germany Retina Health Market Industry**

Public awareness campaigns and screening initiatives spearheaded by health organizations in Germany are instrumental in the early detection and management of retinal diseases. Programs led by Deutscher Blinden- und Sehbehindertenverband e.V. aim to educate the public about the importance of regular eye examinations. Statistics from the German Diabetes Society show that regular screening can help in detecting diabetic retinopathy early, which can affect up to 40% of individuals with diabetes.

By fostering awareness and increasing routine screenings, an essential pipeline for early treatment is created, thereby driving the need for innovative solutions within the Germany Retina Health Market Industry. This heightened focus on preventive healthcare leads to increased visits to ophthalmologists and associated expenditure on retinal health.

### **Germany Retina Health Market Segment Insights**

#### **Retina Health Market Treatment Insights**

The Treatment segment of the Germany Retina Health Market is pivotal in addressing the needs of patients suffering from various retinal disorders, significantly contributing to both patient outcomes and the overall healthcare infrastructure in the country. This segment encompasses a range of approaches, including Drugs, Therapy, and Surgery, each influencing the market in distinct yet interconnected ways.

The Drugs segment plays a critical role, particularly with advancements in pharmacological therapies targeting conditions such as age-related macular degeneration and diabetic retinopathy.

Innovations in drug formulations and delivery mechanisms have underscored the importance of this sub-sector in enhancing patient compliance and therapeutic effectiveness.

Therapy offers a comprehensive framework for managing retinal diseases, utilizing techniques that range from laser treatment to injections, further highlighting the evolving nature of patient care.

This aspect of the Treatment segment is particularly significant given the non-invasive nature of many therapeutic options, appealing to patients seeking effective management with minimal disruption to their daily lives.

Surgery remains a cornerstone of treatment for more advanced cases, where procedural intervention becomes necessary to restore or preserve vision.

This segment typically requires highly specialized skills and technologies, indicative of a robust network of healthcare professionals dedicated to ophthalmic surgery in Germany.

The integration of cutting-edge surgical techniques not only augments the capabilities of practitioners but also enhances patient trust and satisfaction in receiving care. Overall, the Treatment segment of the Germany Retina Health Market illustrates a dynamic interplay between pharmacological advancements, therapeutic techniques, and surgical innovations, driving market growth and meeting the demands of an aging population.

Increased awareness of retinal health issues and favorable reimbursement policies contribute to the burgeoning interest in this area. At the same time, ongoing Research and Development initiatives promise to deliver new solutions and expand the available treatment modalities in the coming years. The emphasis on personalized patient care and the continuous evolution of treatment paradigms will be crucial in shaping the future landscape of the Germany Retina Health Market.

As stakeholders navigate through challenges such as the rising prevalence of retinal disorders, they are also presented with significant opportunities aimed at improving patient outcomes and enhancing the quality of care overall. This vibrant market segment is expected to sustain momentum, driven by a combination of scientific discovery, technological advances, and an unwavering commitment to preserving and enhancing vision.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Retina Health Market Disease Indication Insights**

The Germany Retina Health Market segmentation focused on Disease Indication showcases notable areas of concern, primarily driven by the increasing prevalence of ophthalmic diseases among the aging population. Age-related macular degeneration holds significant importance as it is a leading cause of vision loss in older adults, highlighting the urgent need for effective management and treatment options.

Diabetic Retinopathy, another major concern, has gained prominence due to the rising rates of diabetes, necessitating effective screening and intervention strategies in Germany.

Inherited Retinal Diseases represent a critical area of research and development, given the genetic basis of these conditions, further emphasizing the need for innovative therapies.

Retinoblastoma, while less common, remains a significant focus due to its impact on pediatric health, urging the healthcare system to implement timely diagnostic and treatment protocols.

The Germany Retina Health Market data reflects emerging trends in personalized medicine and advancing technologies, which are expected to enhance patient outcomes across these conditions. Overall, the landscape presents extensive growth opportunities driven by the ongoing advancements in medical research and technology, as well as concerted efforts towards improving healthcare accessibility.

### **Germany Retina Health Market Key Players and Competitive Insights**

The Germany Retina Health Market has been experiencing significant developments and competitive dynamics in recent years, driven by the increasing prevalence of retinal disorders and advancements in treatment options. As a hub for innovative healthcare solutions in Europe, Germany boasts a robust framework for clinical research and technology development, leading to a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms.

The market is characterized by ongoing collaborations, partnerships, and strategic initiatives aimed at enhancing patient outcomes and improving access to advanced therapies. Companies are focusing on expanding their product portfolios and introducing new therapies to address unmet needs while navigating regulatory pathways to gain market approvals in an increasingly stringent environment.

Genentech has established a strong presence in the Germany Retina Health Market, driven by its commitment to innovation in the treatment of ocular diseases.

The company's strengths lie in its extensive research capabilities, robust pipeline, and a portfolio of effective therapies that cater specifically to retinal conditions such as age-related macular degeneration and diabetic retinopathy.

Genentech’s ability to leverage its scientific expertise in developing targeted therapies allows it to maintain a competitive edge in the market.

Additionally, the company engages in collaborative research efforts with leading German ophthalmology institutions to enhance its understanding of retinal diseases and improve treatment outcomes. This commitment to scientific exploration, coupled with its strong market presence and established relationships with healthcare providers, fortifies Genentech's position within the sector.

Ocugen is also a notable player in the Germany Retina Health Market, with a focus on developing and commercializing transformative therapies for vision-threatening diseases.

The company is particularly recognized for its lead product candidate targeting retinal diseases, which aims to address significant gaps in current treatment options.

Ocugen's strategic initiatives in Germany include a focus on orphan drugs and niche therapies that have the potential to meet specific patient needs.

The company enhances its market presence through collaborations and partnerships aimed at accelerating its research and development efforts. Furthermore, Ocugen’s strengths in navigating regulatory frameworks and its commitment to advancing patient care make it a formidable entity in the landscape. This includes an active exploration of potential acquisitions to strengthen its product pipeline and market position in Germany, allowing it to adapt and respond to the evolving demands of the retinal healthcare sector.

#### **Key Companies in the Germany Retina Health Market Include**

### **Germany Retina Health Market Industry Developments**

Recent developments in the Germany Retina Health Market indicate significant activity among key players like Novartis and Regeneron Pharmaceuticals, particularly with advancements in innovative therapies. In August 2023, Genentech announced the initiation of a pivotal trial for its novel retinal drug in Germany, which aims to improve outcomes for patients with age-related macular degeneration.

Santen Pharmaceutical has also unveiled a partnership with local healthcare providers to enhance the accessibility of its treatments across Germany, focusing on retinal diseases. The German market has witnessed a notable increase in market valuation, driven by heightened investment in Research and Development as well as advancements in technology aimed at diagnosing retinal conditions more accurately.

Additionally, Ocugen, a biotechnology company known for its eye therapeutics, has seen a growing presence in Europe, suggesting strategic expansion in the German market. Mergers and acquisitions have been relatively sparse recently, with no major deals reported among the specified companies like Allergan and Bayer within the past year. Overall, the environment remains dynamic as companies continue to innovate and expand their footprint in Germany’s retina health sector, aligning with regional healthcare goals set forth by government initiatives.

### **Germany Retina Health Market Segmentation Insights**

#### **Retina Health Market Treatment Outlook**

#### **Retina Health Market Disease Indication Outlook**

## Market Drivers

### Rising Incidence of Diabetes

The rising incidence of diabetes in Germany is a significant driver for the retina health market. With approximately 7 million individuals diagnosed with diabetes, the risk of developing diabetic retinopathy is alarmingly high. Studies suggest that nearly 30% of diabetic patients may experience some form of retinal damage. This growing health concern necessitates increased screening and treatment options, thereby expanding the market for retina health services. Healthcare providers are likely to focus on integrated care models that address both diabetes management and eye health, further propelling the growth of the retina health market.

### Government Initiatives and Funding

Government initiatives aimed at improving eye health in Germany play a pivotal role in shaping the retina health market. The German government has implemented various programs to enhance access to eye care services, particularly for vulnerable populations. Funding for research and public health campaigns has increased, with allocations reaching €50 million annually for eye health initiatives. These efforts not only promote awareness but also facilitate advancements in treatment options and technologies. As a result, the retina health market is expected to benefit from increased public investment, leading to improved patient outcomes and a broader range of available services.

### Increased Consumer Spending on Health

Increased consumer spending on health and wellness is influencing the retina health market in Germany. As individuals become more health-conscious, there is a noticeable shift towards preventive care and regular health check-ups. Reports indicate that spending on health-related services has risen by 15% over the past three years. This trend is particularly evident in eye care, where consumers are willing to invest in advanced diagnostic and treatment options. Consequently, the retina health market is poised for growth as more individuals prioritize their eye health, leading to higher demand for specialized services and products.

### Technological Innovations in Treatment

Technological innovations are transforming the retina health market in Germany. The introduction of advanced treatment modalities, such as anti-VEGF therapies and retinal implants, has revolutionized the management of retinal diseases. The market for these innovative treatments is projected to grow at a CAGR of 8% over the next five years. Furthermore, the integration of telemedicine and digital health solutions is enhancing patient access to specialized care, particularly in rural areas. These advancements not only improve treatment efficacy but also contribute to better patient compliance and satisfaction, thereby driving the overall growth of the retina health market.

### Aging Population and Eye Health Awareness

The aging population in Germany is a crucial driver for retina health services. As individuals age, the prevalence of age-related eye diseases, such as macular degeneration and diabetic retinopathy, increases significantly. Reports indicate that by 2030, approximately 25% of the German population will be over 65 years old, leading to a heightened demand for retina health services. This demographic shift necessitates increased awareness and education regarding eye health, prompting healthcare providers to focus on preventive measures and early detection. Consequently, the retina health market is likely to expand as more individuals seek regular eye examinations and treatments, thereby driving growth in this sector.

## Future Outlook

The [Retina Health Market](https://www.marketresearchfuture.com/reports/retina-health-market-10913) in Germany is projected to grow at a 6.97% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of retinal diseases, and rising healthcare expenditure.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection of retinal diseases. Expansion of telemedicine services for remote patient monitoring and consultations. Investment in innovative drug delivery systems for targeted retinal therapies.

By 2035, the retina health market is expected to achieve substantial growth, reflecting advancements and increased demand.

## Segment Insights

### By Treatment: Drugs (Largest) vs. Therapy (Fastest-Growing)

The treatment segment in the Germany retina health market reveals a diverse distribution of market share among its key components: drugs, therapy, and surgery. Drugs dominate this space, holding the largest share due to their established efficacy and broad usage in managing various retinal conditions. Therapy options, while currently smaller, are rapidly gaining traction, driven by advancements in non-invasive techniques. Surgery, although crucial for certain conditions, occupies a modest share, primarily relying on its specific applications and less frequent need compared to pharmacological and therapeutic interventions.

In terms of growth trends, therapy is identified as the fastest-growing segment, fueled by increasing awareness of retinal disorders and the aging population, which necessitates more innovative treatment options. Advances in technology are also contributing to the growth of therapy, with new modalities being developed that enhance patient outcomes and comfort. Drugs remain stable, yet innovations in formulations and delivery methods aim to sustain their market position, while surgery continues to evolve with improved techniques but faces challenges in scaling like the other treatments.

Drugs (Dominant) vs. Therapy (Emerging)

In the Germany retina health market, drugs are recognized as the dominant treatment option, attributed to their robust track record in managing retinal diseases such as diabetic retinopathy and age-related macular degeneration. The effectiveness and wide acceptability of drug therapies lead to high patient compliance and favorable clinical outcomes. On the other hand, therapy represents an emerging segment, characterized by innovative treatment modalities such as laser therapy and gene therapy. This segment is gaining popularity due to its non-invasive nature and the increasing emphasis on minimizing patient recovery times. The growing trend towards personalized medicine is also expected to propel the therapy segment further, creating a dynamic interplay between established drug treatments and emerging therapeutic alternatives.

### By Disease Indication: Age-Related Macular Degeneration (Largest) vs. Diabetic Retinopathy (Fastest-Growing)

In the Germany retina health market, Age-Related Macular Degeneration (AMD) represents the largest share among the various disease indications, capturing significant attention from healthcare providers and patients alike. Diabetic Retinopathy, on the other hand, is gaining traction and is recognized as the fastest-growing segment, driven by the increasing prevalence of diabetes across the population.

The growth of these segments is influenced by several factors, including the aging population contributing to AMD cases and the rising incidence of diabetes leading to more cases of Diabetic Retinopathy. Moreover, advancements in treatment options and increased awareness of retinal health are propelling growth across these disease indications, attracting more research and investment into therapies and management strategies.

Age-Related Macular Degeneration (Dominant) vs. Diabetic Retinopathy (Emerging)

Age-Related Macular Degeneration (AMD) is the dominant segment due to its high prevalence among older adults, marking it as a critical area of focus in eye healthcare. This condition is characterized by the degeneration of the retina, leading to significant vision impairment. In contrast, Diabetic Retinopathy, while traditionally seen as less dominant, is emerging rapidly due to rising diabetes rates. This condition affects blood vessels in the retina and can lead to severe vision loss. The growing diabetic patient population and the resulting healthcare initiatives to tackle Diabetic Retinopathy highlight its increasing significance in the market. The contrasting dynamics of these two segments make them pivotal in shaping the future of the Germany retina health market.

## Competitive Benchmarking

The retina health market in Germany is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and advancements in treatment modalities. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Bayer (DE) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Novartis (CH) focuses on developing novel therapies for retinal diseases, while Regeneron Pharmaceuticals (US) emphasizes its robust pipeline of biologics. Bayer (DE) is actively pursuing collaborations to expand its product offerings, indicating a collective strategy among these companies to shape a competitive environment that prioritizes innovation and patient-centric solutions.The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This approach not only reduces costs but also improves responsiveness to market demands. The collective influence of key players fosters a competitive atmosphere where innovation and strategic partnerships are paramount, allowing companies to differentiate themselves in a crowded marketplace.
In October Novartis (CH) announced a strategic partnership with a leading technology firm to integrate AI-driven analytics into its clinical trials for retinal therapies. This move is likely to enhance the efficiency of drug development processes and improve patient outcomes, reflecting a broader trend towards digital transformation in the healthcare sector. The integration of AI could potentially streamline operations and reduce time-to-market for new treatments, positioning Novartis (CH) as a frontrunner in the retina health market.
In September Regeneron Pharmaceuticals (US) received regulatory approval for its latest retinal drug, which is designed to treat age-related macular degeneration (AMD). This approval not only strengthens Regeneron’s product portfolio but also underscores its commitment to addressing unmet medical needs in the retina health space. The successful launch of this drug is expected to significantly impact the company’s revenue streams and market share, further solidifying its competitive stance.
In August Bayer (DE) expanded its collaboration with a European biotech firm to co-develop a new gene therapy for retinal diseases. This strategic alliance is indicative of Bayer’s focus on innovative treatment options and its willingness to invest in cutting-edge research. By pooling resources and expertise, Bayer (DE) aims to accelerate the development of therapies that could transform the treatment landscape for retinal conditions, thereby enhancing its competitive edge.
As of November current trends in the retina health market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a crucial role in shaping the competitive landscape, enabling companies to share knowledge and resources. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in the evolving market.

## Recent News & Developments

Recent developments in the Germany Retina Health Market indicate significant activity among key players like Novartis and Regeneron Pharmaceuticals, particularly with advancements in innovative therapies. In August 2023, Genentech announced the initiation of a pivotal trial for its novel retinal drug in Germany, which aims to improve outcomes for patients with age-related macular degeneration.

Santen Pharmaceutical has also unveiled a partnership with local healthcare providers to enhance the accessibility of its treatments across Germany, focusing on retinal diseases. The German market has witnessed a notable increase in market valuation, driven by heightened investment in Research and Development as well as advancements in technology aimed at diagnosing retinal conditions more accurately.

Additionally, Ocugen, a biotechnology company known for its eye therapeutics, has seen a growing presence in Europe, suggesting strategic expansion in the German market. Mergers and acquisitions have been relatively sparse recently, with no major deals reported among the specified companies like Allergan and Bayer within the past year. Overall, the environment remains dynamic as companies continue to innovate and expand their footprint in Germany’s retina health sector, aligning with regional healthcare goals set forth by government initiatives.

## Report Scope

| MARKET SIZE 2024 | 1120.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1198.06(USD Million) |
| MARKET SIZE 2035 | 2350.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.97% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Santen Pharmaceutical (JP), Carl Zeiss AG (DE), Hoya Corporation (JP) |
| Segments Covered | Treatment, Disease Indication |
| Key Market Opportunities | Advancements in telemedicine and AI-driven diagnostics enhance accessibility in the retina health market. |
| Key Market Dynamics | Technological advancements in retinal therapies drive competitive dynamics and regulatory adaptations in the healthcare landscape. |
| Countries Covered | Germany |

## Frequently Asked Questions

**Q: What is the current valuation of the retina health market in Germany as of 2024?**
A: The overall market valuation was 1120.0 $ Million in 2024.

**Q: What is the projected market valuation for the retina health market in Germany by 2035?**
A: The projected valuation for 2035 is 2350.0 $ Million.

**Q: What is the expected CAGR for the Germany retina health market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 6.97%.

**Q: Which companies are considered key players in the Germany retina health market?**
A: Key players include Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Santen Pharmaceutical (JP), Carl Zeiss AG (DE), and Hoya Corporation (JP).

**Q: What are the main treatment segments in the Germany retina health market?**
A: The main treatment segments include Drugs, Therapy, and Surgery, with valuations ranging from 300.0 to 900.0 $ Million.

**Q: How does the market for Age-Related Macular Degeneration compare to other diseases in the retina health market?**
A: The market for Age-Related Macular Degeneration ranges from $400.0 to $850.0 Million, making it one of the largest segments.

**Q: What is the valuation range for the Diabetic Retinopathy segment in the Germany retina health market?**
A: The valuation range for Diabetic Retinopathy is between 300.0 and 650.0 $ Million.

**Q: What is the expected growth trajectory for Inherited Retinal Diseases in the coming years?**
A: The Inherited Retinal Diseases segment is projected to have a valuation range of 250.0 to 500.0 $ Million.

**Q: What is the valuation range for the Surgery segment in the Germany retina health market?**
A: The Surgery segment has a valuation range from 420.0 to 900.0 $ Million.

**Q: How does the market for Retinoblastoma compare to other disease indications in the retina health market?**
A: The Retinoblastoma segment has a valuation range of 170.0 to 350.0 $ Million, indicating a smaller market compared to others.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/germany-retina-health-market-50119*